Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Angiotensin 1 7 - Constant Therapeutics

Drug Profile

Angiotensin 1 7 - Constant Therapeutics

Alternative Names: TXA-127; USB-002

Latest Information Update: 15 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tarix Orphan; Tarix Pharmaceuticals
  • Developer Constant Therapeutics; Tarix Orphan; Tarix Pharmaceuticals; Unigene Laboratories; US Biotest Inc
  • Class Angiotensins; Antihypertensives; Antiretrovirals; Peptide hormones; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Proto-oncogene protein c-mas-1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa dystrophica; Pulmonary arterial hypertension; Limb girdle muscular dystrophies; Epidermolysis bullosa; Muscular dystrophies; Duchenne muscular dystrophy; Stem cell engraftment; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections
  • Phase II Duchenne muscular dystrophy; SARS-CoV-2 acute respiratory disease; Stroke
  • Preclinical Acute lung injury
  • No development reported Amyotrophic lateral sclerosis; Epidermolysis bullosa; Epidermolysis bullosa dystrophica; Limb girdle muscular dystrophies; Marfan syndrome; Muscular dystrophies
  • Discontinued Adult respiratory distress syndrome; HIV infections; Peripheral vascular disorders; Pulmonary arterial hypertension; Stem cell engraftment; Thrombocytopenia

Most Recent Events

  • 31 Dec 2023 Vanderbilt University Medical Center completes a phase II/III clinical trials in COVID-2019 infections in USA (IV) (NCT04924660)
  • 29 Nov 2023 Phase-II clinical trials in Stroke in Israel (SC) (NCT06135103)
  • 31 Aug 2023 Phase-II clinical trials in Duchenne muscular dystrophy (Treatment-experienced, In adults, In adolescents) in Israel (SC) (NCT06013839)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top